Rifamycin SV in the Treatment of Knee Synovitis

Area of Science:

• Rheumatology
• Pharmacology

Background:

• This study investigated the efficacy of intraarticular Rifamycin SV for treating knee effusions in various arthritic conditions.
• A total of 60 rheumatoid arthritis patients and 20 patients with other arthropathies were included.

Discussion:

• Rifamycin SV demonstrated significant success in eliminating persistent knee effusions across multiple arthritis types.
• Local side effects led to treatment discontinuation in two rheumatoid arthritis patients.
• The number of treatment infiltrations correlated with the local synovitis activity grade.

Key Insights:

• Complete resolution of knee effusions was achieved in 57/60 rheumatoid arthritis patients and all patients with juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, intermittent hydrarthrosis, and chondromatosis.
• A high rate of sustained remission was observed: 50/57 rheumatoid arthritis patients and 19/20 patients from other groups remained effusion-free for extended periods (25-36 months and 12-20 months, respectively).

Outlook:

• While Rifamycin SV exhibits local anti-inflammatory effects in arthritic knee joints, its complete therapeutic action may involve additional mechanisms.
• Further research is warranted to elucidate the comprehensive pharmacological profile and optimize treatment strategies for inflammatory joint diseases.